Collaboration Advances Understanding of the Mechanisms of Drug Resistance to Dual-Agent Chemotherapy in Recurrent Ovarian Cancer
More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main classes of chemotherapy agents used to fight it – platinating agents and taxanes. Now, a study reported in the … Continue reading Collaboration Advances Understanding of the Mechanisms of Drug Resistance to Dual-Agent Chemotherapy in Recurrent Ovarian Cancer